Radiotherapy with or without chemotherapy for patients with T1-T2 glottic carcinoma: Retrospective analysis

Head and Neck Oncology

Volumn 2, Issue 1, 2010, Pages

  Hirasawa, Naoki ^a   Itoh, Yoshiyuki ^a   Ishihara, Shunichi ^a   Kubota, Seiji ^a   Itoh, Junji ^a   Fujimoto, Yasushi ^a   Nakashima, Tsutomu ^a   Naganawa, Shinji ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; UFT; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; DRUG MEGADOSE; FATALITY; FEMALE; HUMAN; LARYNGECTOMY; LARYNX CARCINOMA; LOW DRUG DOSE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NECK METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT FAILURE; TREATMENT RESPONSE; CANCER STAGING; GLOTTIS; LARYNX TUMOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIATION DOSE; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; GLOTTIS; HUMANS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77955530019     PISSN: None     EISSN: 17583284     Source Type: Journal    
DOI: 10.1186/1758-3284-2-20     Document Type: Article

References (27)

1. Laryngeal Cancer Treatment. PDQ - NCI's Comprehensive Cancer Database http://www.cancer.gov/cancertopics/pdq/treatment/laryngeal/healthprofessional
2. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. DG Pfister SA Laurie GS Weinstein WM Mendenhall DJ Adelstein KK Ang GL Clayman SG Fisher AA Forastiere LB Harrison, et al. J Clin Oncol 2006 24 3693 3704 10.1200/JCO.2006.07.4559 16832122
3. Analysis of prognostic factors for T(1)N(0)M(0) glottic cancer treated with definitive radiotherapy alone: experience of the cancer hospital of Peking Union Medical College and the Chinese Academy Of Medical Sciences. J Jin Z Liao L Gao X Huang G Xu, Int J Radiat Oncol Biol Phys 2002 54 471 478 10.1016/S0360-3016(02)03493-4 12243824
4. T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. WM Mendenhall RJ Amdur CG Morris RW Hinerman, J Clin Oncol 2001 19 4029 4036 11600604
5. Radiation therapy in T1-T2 glottic carcinoma: influence of various treatment parameters on local control/complications. KA Dinshaw V Sharma JP Agarwal S Ghosh R Havaldar, Int J Radiat Oncol Biol Phys 2000 48 723 735 11020569
6. Radical radiotherapy for early glottic cancer: Results in a series of 1087 patients from two Italian radiation oncology centers. I. The case of T1N0 disease. E Cellai P Frata SM Magrini F Paiar R Barca S Fondelli C Polli L Livi B Bonetti E Vitali, et al. Int J Radiat Oncol Biol Phys 2005 63 1378 1386 10.1016/j.ijrobp.2005.05.018 16095847 (Pubitemid 41628032)
7. Radical radiotherapy for early glottic cancer: Results in a series of 1087 patients from two Italian radiation oncology centers. II. The case of T2N0 disease. P Frata E Cellai SM Magrini B Bonetti E Vitali S Tonoli M Buglione F Paiar R Barca S Fondelli, et al. Int J Radiat Oncol Biol Phys 2005 63 1387 1394 10.1016/j.ijrobp.2005.05.013 16115737 (Pubitemid 41628033)
8. Larynx. WM Mendenhall RW Hinerman RJ Amdur AA Mancuso DB Villaret JW Werning, Perez and Brady's Principles and Practice of Radiation Oncology Philadelphia: Lippincott Williams & Wilkins, Halperin EC, Perez CA, Brady LW, 5 2007 975 995
9. Effect of tumor bulk on local control and survival of patients with T1 glottic cancer. SP Reddy N Mohideen S Marra JE Marks, Radiother Oncol 1998 47 161 166 10.1016/S0167-8140(97)00196-5 9683364
10. Effect of tumor bulk on local control and survival of patients with T1 glottic cancer: a 30-year experience. SP Reddy RL Hong S Nagda B Emami, Int J Radiat Oncol Biol Phys 2007 69 1389 1394 17869013
11. Heterogeneity of stage II glottic carcinoma and its therapeutic implications. AB Karim JH Kralendonk LY Yap KH Njo AH Tierie RM Tiwari GB Snow GJ Gerritsen A Hasman, Int J Radiat Oncol Biol Phys 1987 13 313 317 3104243
12. Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time. H Yamazaki K Nishiyama E Tanaka M Koizumi M Chatani, Int J Radiat Oncol Biol Phys 2006 64 77 82 16169681
13. Hyperfractionated-accelerated or conventionally fractionated radiotherapy for early glottic cancer. H Haugen KA Johansson C Mercke, Int J Radiat Oncol Biol Phys 2002 52 109 119 11777628
14. Results of radiotherapy for T2N0 glottic carcinoma: does the "2" stand for twice-daily treatment? AS Garden K Forster PF Wong WH Morrison NR Schechter KK Ang, Int J Radiat Oncol Biol Phys 2003 55 322 328 12527044
15. A Randomized Trial of Hyperfractionation Versus Standard Fractionation In T2 Squamous Cell Carcinoma of The Vocal Cord. A Trotti T Pajak B Emami E Hammond C Jones W Morrison S Sagar J Ridge KK Fu K Ang, Int J Radiat Oncol Biol Phys 2006 66 15 16979433
16. Radiation therapy for T2N0 laryngeal cancer: A retrospective analysis for the impact of concurrent chemotherapy on local control. T Akimoto T Nonaka Y Kitamoto H Ishikawa H Ninomiya K Chikamatsu N Furuya K Hayakawa N Mitsuhashi T Nakano, Int J Radiat Oncol Biol Phys 2006 64 995 1001 16406396
17. Retrospective analysis: concurrent chemoradiotherapy using protracted continuous infusion of low-dose cisplatin and 5-fluorouracil for T2N0 glottic cancer. Y Itoh N Fuwa, Radiat Med 2006 24 277 281 10.1007/s11604-005-1517-1 16958401
18. "FAR" chemoradiotherapy improves laryngeal preservation rates in patients with T2N0 glottic carcinoma. Y Kumamoto M Masuda Y Kuratomi S Toh A Shinokuma K Chujo T Yamamoto S Komiyama, Head Neck 2002 24 637 642 10.1002/hed.10114 12112536
19. A phase I study of concurrent chemoradiotherapy with S-1 for T2N0 glottic carcinoma. H Tsuji T Kiba M Nagata T Inoue H Yukawa T Yamashita Y Shimode H Murata K Nagata K Tomoda, Oncology 2006 71 369 373 10.1159/000108385 17851262
20. Effectiveness of concurrent radiation therapy with UFT or TS-1 for T2N0 glottic cancer in Japan. Y Niibe M Nakayama T Matsubayashi H Takahashi M Kitano M Okamoto K Hayakawa, Anticancer Res 2007 27 3497 3500 17972507
21. DNA ploidy analysis performed prospectively using fresh tumor samples in early glottic carcinoma treated with radiotherapy. N Ii N Fuwa M Ando Y Itoh Y Nomoto K Takeda, Int J Radiat Oncol Biol Phys 2002 52 415 419 11872287
22. Ki-67, p53 and epidermal growth factor receptor expression in early glottic cancer involving the anterior commissure treated with radiotherapy. WA Ahmed K Suzuki Y Imaeda Y Horibe, Auris Nasus Larynx 2008 35 213 219 17996416
23. P53 overexpression is associated with bulky tumor and poor local control in T1 glottic cancer. A Narayana AT Vaughan S Kathuria SG Fisher SA Walter SP Reddy, Int J Radiat Oncol Biol Phys 2000 46 21 26 10.1016/S0360-3016(99)00348-X 10656367
24. Overexpression of Bcl-2 in squamous cell carcinoma of the larynx: a marker of radioresistance. LT Condon JN Ashman SR Ell ND Stafford J Greenman L Cawkwell, Int J Cancer 2002 100 472 475 10.1002/ijc.10503 12115532
25. Total microvessel perimeter per tumor area is a predictor of radiosensitivity in early-stage glottic carcinoma. S Zhang R Hayashi M Fujii Y Hasegawa K Yoshino M Fukayama A Ochiai, Int J Radiat Oncol Biol Phys 2009 73 1104 1109 18950960
26. Second malignant neoplasia in patients with T1 glottic cancer treated with radiation. M Fujita MS Rudoltz DJ Canady P Patel M Machtay MQ Pittard M Mohiuddin WF Regine, Laryngoscope 1998 108 1853 1855 10.1097/00005537-199812000- 00016 9851503
27. Radiotherapy for patients with early-stage glottic carcinoma: univariate and multivariate analyses in a group of consecutive, unselected patients. G Franchin E Minatel C Gobitti R Talamini E Vaccher G Sartor D Politi MG Trovo L Barzan, Cancer 2003 98 765 772 10.1002/cncr.11575 12910521